Ginkgo biloba is one of the oldest living tree species on Earth — a living fossil with no close botanical relatives, virtually unchanged from the Ginkgo fossils found in Permian-era rocks approximately 270 million years old. Its extract, prepared from the leaves of the tree, has been used in traditional Chinese medicine for thousands of years for respiratory and circulatory conditions, and it is one of the most prescribed plant medicines in Europe today, particularly in Germany and France, where it is standard care in geriatric medicine for age-related cognitive decline and circulatory insufficiency.
Mechanism: Blood Flow and Beyond
Ginkgo’s primary mechanism involves its effects on the vascular system: it is a potent inhibitor of platelet-activating factor (PAF), the signalling molecule that activates platelet aggregation. By inhibiting PAF, ginkgo reduces the aggregation of platelets and improves blood flow to small capillaries throughout the body, including the cerebral microcirculation. This is particularly relevant for older adults, where age-related increases in PAF contribute to the reduced cerebral blood flow and the consequent cognitive decline that accompanies normal ageing.
Beyond its PAF-inhibiting effects, ginkgo also acts as an antioxidant in the brain — it scavenges free radicals, reduces lipid peroxidation in neuronal membranes, and has been shown to protect against amyloid-beta toxicity in cell culture models of Alzheimer’s disease. It also modulates the cholinergic system, increasing acetylcholine release and slowing its breakdown — effects that are mechanistically similar to the cholinesterase inhibitors used in Alzheimer’s disease treatment.
The Clinical Evidence for Cognitive Ageing
The evidence for ginkgo in age-related cognitive decline is mixed but trending positive. The largest and most rigorous trial — the Ginkgo Evaluation of Memory (GEM) study, a double-blind RCT in 3,069 adults over 75 followed for 6 years — found no overall effect on dementia incidence or cognitive decline. However, a prespecified subgroup analysis suggested a possible reduction in dementia incidence in the subset of participants with no baseline cognitive impairment. More recent meta-analyses that include trials in younger populations and in people with mild cognitive impairment (MCI) have found more consistently positive effects: ginkgo at 120-240mg daily improves cognitive performance on tests of attention, memory, and processing speed in people with MCI and in age-related cognitive decline.
Ginkgo for Tinnitus and Circulatory Insufficiency
One of the most clinically relevant uses of ginkgo is in the treatment of tinnitus (ringing in the ears) associated with cerebral circulatory insufficiency. The PAF-inhibiting effect of ginkgo improves blood flow in the small capillaries of the inner ear and brain, and several RCTs have shown that ginkgo at 120-240mg daily significantly reduces tinnitus severity compared to placebo, particularly in people whose tinnitus is associated with dizziness or other symptoms of circulatory insufficiency. The related application is in peripheral arterial disease (intermittent claudication), where reduced blood flow to the legs produces cramping pain during walking that resolves with rest.
Dosing and Quality Considerations
The evidence-based dose for cognitive and circulatory applications is 120-240mg daily of a standardised ginkgo extract (typically 24% flavonoid glycosides and 6% terpene lactones). The most common form is EGb 761, the standardised extract used in most of the clinical trials. Quality matters significantly for ginkgo: the crude leaf contains compounds (ginkgolic acids) that are potentially allergenic and that should be below 5ppm in a quality extract. Ginkgo should not be combined with anticoagulants (warfarin, clopidogrel, aspirin) without close medical supervision because of its antiplatelet effects.
The Science Behind Methylene Blue Nootropic Effects
Methylene blue is a phenothiazine dye that has been used in medicine for over 140 years — initially as an antimalarial, later as a treatment for methemoglobinemia and cyanide poisoning. Its nootropic properties emerged from observations that at low doses (0.5-4 mg/kg), it acts as an electron donor in the mitochondrial electron transport chain, specifically at Complex I (NADH dehydrogenase). By donating electrons directly to Complex I, methylene blue improves the efficiency of ATP production in neurons, reduces reactive oxygen species generation at Complex III, and enhances mitochondrial respiration. This is particularly relevant for neurons because they are highly energy-dependent and particularly vulnerable to mitochondrial dysfunction.
Memory and Long-Term Potentiation
Studies on animal models demonstrate that methylene blue at low doses enhances long-term potentiation (LTP) — the cellular basis of memory formation in the hippocampus. Methylene blue increases mitochondrial biogenesis in hippocampal neurons, improves calcium handling, and enhances synaptic plasticity-related gene expression. In humans, preliminary studies suggest improvements in short-term memory, working memory, and attention, particularly in tasks requiring sustained concentration. A 2015 study found that methylene blue improved fMRI BOLD signal in the prefrontal cortex during working memory tasks, suggesting increased neural efficiency in the circuits most important for executive function.
Safety and Legality
Methylene blue is FDA-approved for the treatment of methemoglobinemia and is available by prescription. As an over-the-counter supplement ingredient, it occupies a legal grey area — it is not scheduled, but the FDA has issued warning letters to companies marketing it as a supplement. Self-experimentation with methylene blue should only be done with pharmaceutical-grade product at low doses (0.5-2 mg/kg), and it should not be combined with serotonergic medications (SSRIs, MAOIs) due to the risk of serotonin syndrome. At higher doses (above 5 mg/kg), methylene blue acts as a potent MAO inhibitor and carries significant risks.
Leave a Reply